Medicortex Finland is dedicated to improving the diagnostics, treatment and prevention of acute neurodegenerative conditions. Current focus is on developing a novel biomarker based diagnostic test for traumatic brain injuries (TBI). After the development project the company will focus on a multiplex treatment for TBI.

Our Vision

Medicortex is determined to become a revolutionary biotech company. The lack of an accurate diagnostics test and a competent neuro-protective medication for brain injury are one of the largest and most serious unmet medical needs in the world today.

Medicortex’s aim is to develop a simple, easy-to-use and relatively cheap test based on a biomarker found in one of the body fluids. Ideally, the test could be applied within minutes of the initial insult.

A biomarker diagnostic test for TBI may be of use in identifying individuals with severe TBI, who are at risk of secondary brain injury and therefore require increased surveillance, or for those individuals with mild TBI, who otherwise may remain undiagnosed and untreated. A diagnostic test can also be applied in cases where there are no external signs of injury, for example for soldiers exposed to blast or explosion injuries.  

We firmly believe that our pipeline represents by far the most logical approach to meeting that dire medical need. The time to move forward is now. Many statistical studies have indicated that TBI and ABI are both on the rise, and not simply because of population growth. Be it increasing longevity, private automobile use, sports and recreation participation or soldiering, the burden of brain injury is only going to rise in the coming years – and Medicortex will be at the forefront of finding a solution.